Prof. Haruhiko Inufusa #1 @ FLOGEN SIPS 2022 Yoshikawa Intl. Symposium on Oxidative Stress

FLOGEN SIPS 2022: Yoshikawa International Symposium on Oxidative Stress for Sustainable Development of Human Beings (2nd international Symposium)

Presenter:
Prof. Haruhiko Inufusa, TIMA, Gifu, Japan

Title:
Antioxidant treatment for Sleep Apnea

Abstract
The number of severely ill patients requiring treatment for sleep apnea syndrome (SAS) is estimated to be over 9 million in Japan and 400 million worldwide. The Space Shuttle Challenger tragedy and the Exxon Valdez maritime accident were caused by SAS, resulting in significant global economic losses. The only effective treatment currently available is CPAP, a forced-air ventilator worn during sleep, which is often discontinued by patients due to its complexity and noise. About 70% of SAS patients have elevated mCRP and oxidative stress in their blood, indicating inflammation somewhere in the body.　Twendee X (TWX) is a very strong antioxidant composition and reduces inflammation which contains L-glutamine, ascorbic acid (VC), L-cystine, coenzyme Q10, succinic acid, fumaric acid, vitamin B2, and niacin. Clinical research of SAS using TWX for SAS was conducted at Takashima Clinic, Utsunomiya Japan. A survey of SAS patients was also conducted at Eyez Inc.The number of snoring as a major symptom of SAS was monitored. 2 weeks of treatment with TWX significantly reduced the number of snoring in 3 out of 5 patients, and 4 weeks of treatment significantly reduced the number of snoring in all 5 patients. 4 weeks of treatment with TWX showed the following effects in 30 SAS patients. TWX reduced snoring by 85%, nighttime waking phenomenon by 84%, deep sleep by 91%, daytime sleepiness by 84%, apnea by 85%, and headache upon awakening by 96%. TWX is a supplement with no side effects and can be safely taken by children, suggesting that it may be effective for about 80% of SAS patients.

References:

1). Novel compositions and uses thereof WO 2008071790 A3\n

2). Antioxidant composition and its use in diabetes EP 1932542 A1\n

3). Pretreatment Twendee X® reduced acute ischemic brain damage. Kusaki M, Inufusa H, Abe K, JSCVD 2017; 26: 1191-1196\n

4). Clinical and Pathological Benefit of Twendee X in Alzheimer's Disease Transgenic Mice with Chronic Cerebral Hypoperfusion. Liu Xia, Yamashita T, Abe K, et al. J Stroke Cerebrovasc Dis. 2019 Jul;28(7):1993-2002.